Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
SG5-H5254 | Human | Human Siglec-15 / CD33L3 Protein, Mouse IgG2a Fc Tag (MALS verified) |
|
||
SG5-C5253 | Rhesus macaque | Rhesus macaque Siglec-15 / CD33L3 Protein, Fc Tag |
|
||
SG5-H82F5 | Human | Biotinylated Human Siglec-15 / CD33L3 Protein, Fc,Avitag™ |
|
||
SG5-H82E9 | Human | Biotinylated Human Siglec-15 / CD33L3 Protein, His,Avitag™ (recommended for biopanning) |
|
||
SG5-M52H7 | Mouse | Mouse Siglec-15 / CD33L3 Protein, His Tag |
|
||
SG5-C52H6 | Rhesus macaque | Rhesus macaque Siglec-15 / CD33L3 Protein, His Tag |
|
||
SG5-H5253 | Human | Human Siglec-15 / CD33L3 Protein, Fc Tag |
|
||
SG5-H52H3 | Human | Human Siglec-15 / CD33L3 Protein, His Tag (MALS verified) |
|
Biotinylated Human Siglec-15, Fc,Avitag (Cat. No. SG5-H82F5) inhibits Anti-CD3-induced proliferation of PBMC. The ED50 for this effect is 0.48-0.57 μg/mL (Routinely tested).
Immobilized Neu5Ac(a2-6)GalNAc-PAA-biotin on SA Chip can bind Human Siglec-15, Fc Tag (Cat. No. SG5-H5253) with an affinity constant of 4.49 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NC-318 | NC-318; 5G-12 | Phase 2 Clinical | Yale School Of Medicine | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Cholangiocarcinoma; Breast Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
DS-1501 | DS-1501 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Osteoporosis | Details |
PYX-106 | PYX-106; BSI-060T | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
NC-318 | NC-318; 5G-12 | Phase 2 Clinical | Yale School Of Medicine | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Cholangiocarcinoma; Breast Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
DS-1501 | DS-1501 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Osteoporosis | Details |
PYX-106 | PYX-106; BSI-060T | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.